Does a pilot study indicating that bradykinin B2 receptor antagonism attenuate protamine-related hypotension after cardiopulmonary bypass?
Increased bradykinin contributes to protamine-related hypotension through its B(2) receptor in ACE inhibitor-treated patients.
RIPerC is effective alone after embolic middle cerebral artery occlusion and has additive effects in combination with intravenous tPA. RIPerC may be a simple, safe, and inexpensive combination therapy with intravenous tPA.